Expression analysis of drug-resistant gene (blaOXA-51) in carbapenemases producing Acinetobacter baumannii treated with imipenem/sulbactam combination

Drug-resistant Acinetobacter baumannii is a frightening reality. The aim of this study is to examine the expression profiles of blaOXA-51 gene in carbapenemases producing A. baumannii treated with imipenem/sulbactam combination. Carbapenemases producing A. baumannii was identified among clinical isolates of A. baumannii obtained from patients at Shahid Rajaee hospital, Gachsaran, Iran, from January to June 2018. Synergism testing of imipenem/sulbactam on carbapenemases producing A. baumannii was carried out by broth microdilution method. Eventually, the expression of blaOXA-51 gene was carried out to investigate the inhibitory properties of imipenem/sulbactam combination against carbapenemases producing A. baumannii using quantitative real time RT-PCR. Among A. baumannii isolates, 24% were carbapenemases producing A. baumannii. Imipenem/sulbactam combination revealed synergistic and partial synergistic effect for all tested isolates (FIC= 0.313-0.75). Finally, imipenem/sulbactam combination displayed significant down-regulation of blaOXA-51 gene in carbapenemases producing A. baumannii. Imipenem synergizes with sulbactam against carbapenemases producing A. baumannii by targeting of the blaOXA-51 gene.

[Spreading and mechanisms of antimicrobial resistance of microorganisms, producing beta-lactamases. Phenotypical screening for MBL producers (carbapenemases B1) among strains of Pseudomonas genus, isolated in cases of nosocomial infections].

Intrahospital strains (215) of the bacterial genus Pseudomonas isolated from patients of 30 Medical centers of 15 Russian regions have been investigated for antibiotic resistance. The bacterial cultures resistant to imipenem and/or meropenem were considered as metallo-beta-lactamase (MBL) producers. Production of subclass B1 MBL (carbapenemases) was evaluated by means of the double-disk approximation test using MBL inhibitor, EDTA. There were 55 P. aeroginosa strains (25.6%) resistant to imipenem and meropenem simultaneously; 19 isolates (8.8%) of P. aeroginosa were characterized by synergism between carbapenem and EDTA. The subclass B1 MBL producers are widely distributed in the intrahospital strain obtained from Moscow, Yaroslavl, Ekaterinburg, Omsk, and Tomsk hospitals.